{
Roche Holding AG

Companies

}
001122334455554433221100
001122334455554433221100

Swiss stock market edges up as Oerlikon and Basilea report strong results

The Swiss stock market closed slightly higher, with the SMI rising 0.15% to 12,893.98 points, buoyed by gains in cyclical and financial stocks. Notable performers included OC Oerlikon (+8.7%) and Basilea (+8.3%), while Lonza (-2.7%) and Siegfried (-6.3%) faced declines due to conservative outlooks. Encouraging economic signals from Germany and the USA contributed to a positive market sentiment.
Finanz und Wirtschaft
United States Dollar Euro Swiss Franc Straumann Holding AG Roche Holding AG Lonza Group AG ABB Ltd Sandoz Group AG Julius Bär Gruppe AG Alstom SA Novartis AG Swiss Re AG Nestlé S.A. Zurich, Agence générale Christian Meier SA OC Oerlikon Corp AG, Pfaffikon DEU USA CHE Show more
Finance & Economy, Market Report
08:06 18.02.2025

analysts update recommendations and price targets for major european companies

Analysts have made several notable changes to their recommendations and price targets for various companies. Adecco Group was downgraded by Deutsche Bank, while Ahold Delhaize saw its target raised by KBC Securities. Anheuser-Busch Inbev received an upgrade from ING Bank, and Ferrari's target was increased by Jefferies. Other significant adjustments include downgrades for Porsche and Fevertree Drinks, alongside upgrades for companies like Victrex and Soitec.
Zonebourse
British Pound Sterling Swiss Franc Euro United States Dollar Norwegian Krone Credit Agricole Roche Holding AG Vinci SA L'Oréal Spectris plc Rational AG Aurubis AG BPER Banca SpA Victrex plc Fagerhult Group AB Nordic Semiconductor ASA Safestore Holdings Plc BNP Paribas SA Safran S.A. (ADRs) Technip Energies N.V. Soitec SA Anheuser-Busch InBev SA/NV Marimekko Oyj Novartis AG Interroll Holding AG X-FAB Silicon Foundries SE Outokumpu Oyj Heineken N.V. Pluxee A Iveco Group N.V. International Consolidated Airlines Group S.A. Koninklijke Ahold Delhaize N.V. The Swatch Group AG Ferrari N.V. UBS Group AG Kongsberg Gruppen ASA Adecco Group AG Atea ASA Fevertree Drinks PLC Ørsted A/S Pennon Group Plc Hermes International Laboratorios Farmaceuticos Rovi, S.A. NOR DEU FRA GBR SWE ITA DNK CHE NLD Show more
Business & Industry, Market Report
08:44 10.02.2025

ubs rates roche holdings ag as neutral amid investment risks

UBS has rated Roche Holdings AG as 'Neutral'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing carries risks, including the potential loss of capital, and expert investment advice is recommended.
wallstreetONLINE
Roche Holding AG CHE
Finance & Economy, Market Report
11:21 31.01.2025

ubs raises roche price target to 300 francs maintains neutral rating

UBS has increased its price target for Roche from 270 to 300 francs while maintaining a "Neutral" rating. Analyst Matthew Weston based this adjustment on 2025 estimates, making minimal changes to forecasts through 2029. Roche operates in pharmaceuticals and diagnostics, developing treatments across various disease areas.
MarketScreener
Swiss Franc Roche Holding AG CHE Matthew Weston Show more
Finance & Economy, Market Report
11:09 31.01.2025

Roche reports modest sales growth and positive earnings outlook for 2025

Roche Holding AG reported a 3% increase in sales for 2024, reaching CHF 60.5 billion, slightly below expectations. The diagnostics segment declined by 1%, while the pharma division grew by 4%, driven by a 68% surge in sales of the eye medicine Vabysmo. The company anticipates mid-single-digit sales growth and high single-digit earnings growth for 2025, with a planned dividend increase.
aktiencheck.de
Swiss Franc Roche Holding AG CHE Raphael Schicho
Finance & Economy, Market Report
11:37 30.01.2025

ubs maintains neutral rating on roche ahead of annual results

UBS has maintained a 'Neutral' rating on Roche, with analyst Matthew Weston highlighting that the focus of the upcoming annual results will likely be on the company's outlook for 2025. Roche operates in two main divisions: Pharmaceuticals and Diagnostics, developing treatments across various disease areas. The last closing price was 279.30 CHF, with an average target price of 302.71 CHF, indicating a potential upside of 8.38%.
MarketScreener
Swiss Franc Roche Holding AG CHE Matthew Weston Show more
Business & Industry, Market Report
22:37 27.01.2025

eli lilly acquires scorpion therapeutics for 2.5 billion in breast cancer push

Eli Lilly has announced a $2.5 billion acquisition of Scorpion Therapeutics’ PI3Kα pipeline, aiming to compete in the breast cancer market against Novartis and Roche. The deal includes the promising candidate STX-478, which has shown a 23% response rate in patients and is designed to selectively target mutant PI3Kα, potentially avoiding adverse effects seen with existing treatments. Lilly will also create a new company for Scorpion's non-PI3Kα assets, retaining Scorpion's staff.
Fierce Biotech
Novartis International AG Roche Holding AG Eli Lilly and Company Relay Therapeutics, Inc. USA Daniel M. Skovronsky Show more
Healthcare, Market Report
15:55 13.01.2025

Roche Holding sees 3.8 percent surge as individual investors benefit

Roche Holding AG's stock surged 3.8%, benefiting individual investors who own 56% of shares, while institutions gained 36%. The top 25 shareholders control less than half of the company, indicating a widely dispersed ownership structure. Insider ownership aligns interests with shareholders, as board members hold CHF19 billion in shares.
simplywall.st
Swiss Franc Roche Holding AG CHE USA Andreas Oeri
Finance & Economy, Market Report
05:05 13.01.2025

roche completes 1.5 billion acquisition of poseida therapeutics

Roche Holdings has finalized its tender offer to acquire Poseida Therapeutics for approximately $1.5 billion, agreeing to pay $9.00 per share for nearly 65 million shares, representing 66% of Poseida’s outstanding stock. The deal includes a potential additional payment of up to $4.00 per share. Following the acquisition, Poseida will become a wholly owned subsidiary of Roche, and its shares will be delisted from the Nasdaq Global Select Market.
TipRanks Financial
United States Dollar Poseida Therapeutics, Inc. Roche Holding AG CHE USA Kirti Tak
Finance & Economy, Press Release
11:14 08.01.2025

semaglutides market projected to reach 36.87 billion by 2028

The semaglutides market is projected to grow from $20.54 billion in 2023 to $36.87 billion by 2028, driven by rising diabetes prevalence and increased demand for effective treatments. Key players are innovating with GLP-1 receptor analogues and oral formulations to enhance patient adherence and reduce side effects. North America leads the market, while Asia-Pacific is expected to be the fastest-growing region.
GlobeNewswire News Room
United States Dollar Adocia SA Sanofi SA Eli Lilly and Company Roche Holding AG Pfizer Inc. Merck & Co., Inc. Dr. Reddy's Laboratories Limited Boehringer Ingelheim International GmbH Glaxosmithkline plc Takeda Pharmaceutical Company Limited AbbVie Inc. Novartis International AG Bristol-Myers Squibb Company Novo Nordisk A/S Cipla Limited Biocon Limited Teva Pharmaceutical Industries Ltd AstraZeneca PLC Amgen Inc. ITA IND FRA IDN CAN ESP BRA USA RUS CHN DEU AUS JPN GBR KOR Show more
Healthcare, Market Report
10:12 06.01.2025
Trending
Subcategory
Corporate News Stock Market Updates Industry Trends Banking Regulations Finance Mergers & Acquisitions Retail and Consumer Goods Global Financial Events Industry Mergers & Acquisitions CEO Changes Workplace Trends Central Bank Actions Global Trade Developments Market Analysis and Predictions Financial Scams and Security Government Policies GDP Growth & Recession Forecasts Inflation and Monetary Impact Supply Chain Management Government Economic Policies Startups & Entrepreneurship
Countries:
USA CHN CHE GBR DEU FRA ITA CAN IND JPN MEX ESP HKG AUS ARE DNK RUS NLD KOR BRA
Companies:
JPMorgan Chase & Co. The Goldman Sachs Group, Inc. Tesla, Inc. Barclays PLC Apple Inc. Deutsche Bank Money Market PP Bank of America Corporation Credit Suisse Lux Digital Healt Citigroup Inc. Wells Fargo & Company UBS Group AG BNP Paribas SA Banco Santander, S.A. Morgan Stanley Lloyds Banking Group plc Commerzbank AG UniCredit S.p.A. Huawei Technologies CO. Ltd. SpaceXCoin USD Berkshire Hathaway Inc.
Currencies:
United States Dollar Euro British Pound Sterling Chinese Yuan Swiss Franc Japanese Yen Indian Rupee Australian Dollar Russian Ruble Danish Krone Canadian Dollar Mexican Peso United Arab Emirates Dirham South Korean Won Offshore Chinese Yuan Hong Kong Dollar Indonesian Rupiah Saudi Riyal Turkish Lira Malaysian Ringgit
People:
Donald Trump Elon Musk Warren Buffett Joe Biden Troy L Rohrbaugh Robin Leopold Christian Sewing Goldman Sachs Brad Schimel Solita Marcelli Stacey Friedman Sabrina Meng Bruno Marxer Will Hardcastle Susan P. Crawford Meng Wanzhou Ulrike Hoffmann-Burchardi Jerome Powell Kirsty Roth Klaus Moosmayer

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.